Clinical Trial Update: 18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease [Phase 1]

View source ↗

Summary

18-month safety-follow-up results from AADvac1, an active tau vaccine for Alzheimer's disease (Phase 1).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• AADvac1

Snippet

Sponsor: Axon Neuroscience SE | Conditions: Alzheimer's Disease | Phase 1 | Status: COMPLETED